The nicotinic a5 subunit is necessary for the acquisition of nicotine-SA in rats d a5SNP rats (rs16969968 polymorphism) self-administer more nicotine at high doses d a5SNP rats exhibit higher nicotine-induced reinstatement of nicotine seeking d Activation of interpeduncular nucleus neurons by nicotine is reduced in a5SNP rats
In Brief Forget et al. show that transgenic rats expressing a human nicotinic receptor polymorphism self-administer more nicotine at high doses and exhibit higher nicotine-induced reinstatement of nicotine seeking than wild-types. This relapse is associated with reduced neuronal activity in the interpeduncular nucleus.
SUMMARY
Tobacco addiction is a chronic and relapsing disorder with an important genetic component that represents a major public health issue. Meta-analysis of large-scale human genome-wide association studies (GWASs) identified a frequent non-synonymous SNP in the gene coding for the a5 subunit of nicotinic acetylcholine receptors (a5SNP), which significantly increases the risk for tobacco dependence and delays smoking cessation. To dissect the neuronal mechanisms underlying the vulnerability to nicotine addiction in carriers of the a5SNP, we created rats expressing this polymorphism using zinc finger nuclease technology and evaluated their behavior under the intravenous nicotine-self-administration paradigm. The electrophysiological responses of their neurons to nicotine were also evaluated. a5SNP rats selfadministered more nicotine at high doses and exhibited higher nicotine-induced reinstatement of nicotine seeking than wild-type rats. Higher reinstatement was associated with altered neuronal activity in several discrete areas that are interconnected, including in the interpeduncular nucleus (IPN), a GABAergic structure that strongly expresses a5-containing nicotinic receptors. The altered reactivity of IPN neurons of a5SNP rats to nicotine was confirmed electrophysiologically. In conclusion, the a5SNP polymorphism is a major risk factor for nicotine intake at high doses and for relapse to nicotine seeking in rats, a dual effect that reflects the human condition. Our results also suggest an important role for the IPN in the higher relapse to nicotine seeking observed in a5SNP rats.
INTRODUCTION
Tobacco addiction, a chronic and relapsing disorder, is expected to contribute to 100 million deaths worldwide this century [1] . Nicotine, the principal psychoactive substance of tobacco smoke that leads to addiction, is a potent agonist for nicotinic acetylcholine receptors (nAChRs) [2] . These pentameric, ligand-gated ion channels are abundant throughout the brain, where different subunits (a2-a6, a7, and b2-b4) co-assemble in varying combinations with diverse functional properties [3] . The elucidation of the biological action of nicotine on addiction-like processes in general, and on relapse in particular, addresses an urgent public health issue. It is well established that genetic and environmental factors influence tobacco dependence [4] . Recently, several independent large-scale human genomewide association studies (GWASs) identified variants in a region on human chromosome 15 encoding the a3, a5, and b4 nAChR subunits that increase the risk for nicotine dependence [5] [6] [7] . One of these variants, the non-synonymous SNP rs16969968 found in exon 5 of the a5 gene (a5SNP), causes an amino acid change D398N. This SNP is very frequent in the general population, in approximately 35% of Europeans and 50% of Middle Eastern populations, and has been associated with an increased risk for nicotine dependence, lower ratings of aversive effect, cognitive enhancement following nicotine administration, and delayed smoking cessation [6, [8] [9] [10] .
The a5 nAChR subunit is expressed in discrete regions of the mammalian CNS, including the cerebral cortex, cerebellum, thalamus, striatum, hippocampus, substantia nigra, interpeduncular nucleus (IPN), ventral tegmental area (VTA), and medial habenula (mHb) [11, 12] .
The role of the a5 subunit and the consequences of the presence of the minor variant rs16969968 (a5SNP) have to some extent been investigated in vitro and in animal models of nicotine addiction. In vitro data suggest that the a5SNP confers a partial loss of function to the nAChRs in which it is expressed [6, 13, 14] , including in human induced pluripotent stem (iPS)-derived neurons [15] . In vivo studies showed that mice lacking the a5 subunit, or rats with downregulation of the a5 subunit in the mHb, increase their nicotine self-administration at high doses [16, 17] . In addition, data from our laboratory demonstrated that mice lacking the a5 subunit and expressing the a5SNP subunit specifically in dopaminergic (DA) neurons of the VTA exhibit an increase in self-administration of high nicotine doses and a reduction in responsiveness of DA neurons to nicotine injections [17] . However, these studies did not investigate the involvement of the a5 subunit in features linked to extended nicotine intake, such as relapse to nicotine seeking after extinction, a critical facet of the addiction process. Furthermore, these studies did not assess the consequences of the constitutive presence of the a5SNP, which is the only valid model of the human condition.
Considering that intravenous nicotine self-administration can be maintained for longer periods in rats than in mice with nicotine plasma level more similar to what is observed in human smokers [18] , we created knockout rats for the a5 subunit (a5KO rats) and knockin rats constitutively expressing the a5SNP (a5SNP rats). Until recently, the toolbox of rat genetics lacked the ability to easily introduce site-directed, heritable mutations into the genome to create knockout or knockin rats. This is now possible with the development of programmable nuclease technology [19] , such as the zinc finger nuclease (ZFN) technology that induces sequence-specific doublestrandbreaks when injected into the pronucleus of single-cell embryos [20] , and is accompanied by negligible off-target activity compared to CRISPR/Cas9 technology [21, 22] .
The a5KO and a5SNP rats generated with ZFN technology were then used to investigate the impact of the a5SNP and of the gene deletion on multiple behaviors related to nicotine addiction and, in particular, on several procedures of reinstatement of nicotine seeking after extinction, a valid model of relapse [23] . Behavioral experiments were combined with c-Fos immunostaining to correlate neuronal responses to nicotine with relapse to nicotine seeking and completed with in vivo and ex vivo electrophysiological studies.
RESULTS

Creation and Validation of a5KO and a5SNP Rats
To create a5KO rats, the ZFN pair was designed to target the beginning of exon 5 of the nAChR a5 subunit gene, which codes for most of the transmembrane domains of the subunit [24] . The ZFN pair was injected into the pronucleus of rat single-cell embryo. Screening 40 founder rats yielded 13 (32.5%) that harbored genetic modifications at the locus of interest, and sequencing revealed mostly deletions, from 10 to 184 bp. For the a5SNP rat line, the ZFN pair was designed to target the end of exon 5, 50 base pairs away from the rs16969968 polymorphism location. The ZFN pair was injected into the pronucleus of rat single-cell embryos with a template DNA of 1,603 bp homology and containing the a5SNP at its center. Screening 26 founder rats yielded 3 (11.5%) that harbored the insertion of the a5SNP at the locus of interest. Multiple conditions were tested, and the results are summarized in Figure S1 .
The primers used for genotyping and the characteristics of the ZFNs are indicated in Figure S2 .
Two founders were chosen to generate the a5KO and a5SNP lines, respectively, because of the presence of a large 184-bp deletion or of the presence of the a5SNP, with no additional modifications (Figures 1A and 1B) and no off-target alterations ( Figures S3A and S4A ).
We then investigated by immunoprecipitation (IP) with subunitspecific antibodies the levels of a5 subunits and of total heteromeric nAChRs in multiple brain areas. The majority of a5 subunit proteins were detected in the IPN ( Figure 1C ). We did not observe any significant differences between the levels of a5-containing nAChRs (a5*nAChRs) in a5SNP and wild-type (WT) rats, in every brain area tested. In contrast, the a5 subunit protein was not detectable in a5KO rats, confirming gene deletion. There was overall no modification in the total number of hetero-oligomeric receptors in any of the brain areas analyzed of a5KO or a5SNP rats ( Figure 1D ).
Nicotine Self-Administration of a5SNP, a5KO, and WT Rats a5SNP, a5KO, and WT rats were then submitted to chronic intravenous nicotine self-administration (nicotine-SA), the gold standard model for investigating the reinforcing effects of nicotine [25] (see STAR Methods). We analyzed the acquisition of the behavior by progressively increasing the number of active lever presses necessary for the rats to obtain an injection of nicotine (0.03 mg/kg/infusion) from 1 to 5 over 15 sessions (Figure 2A) . Although a5SNP and WT rats acquired nicotine-SA similarly, a5KO rats failed to do so, especially when the ratio to obtain a nicotine injection increased to 5 (Figure 2A ). Thus, in our conditions, a5KO rats were unable to acquire nicotine-SA at this dose. This effect seems specific to nicotine because the three groups acquired food-SA similarly ( Figure 2B ).
a5SNP and WT rats were then allowed to self-administer multiple doses of nicotine according to a Latin square design (0-0.09 mg/kg/injection) to establish a dose-response curve. a5SNP and WT rats self-administered the same amount of nicotine at 0.01 and 0.03 mg/kg, but a5SNP rats consumed significantly more nicotine at higher doses (0.06 and 0.09 mg/kg; Figure 2C ). When saline was substituted for nicotine during consecutive sessions, rats of both groups displayed similar extinction of their active lever-pressing behavior ( Figure 2D ), indicating that nicotine expectation drives the lever-pressing behavior and that the a5SNP has no effect on extinction. We then shifted the schedule of reinforcement to a progressive ratio, as previously described [26] , allowing the measurement of the incentive motivational and rewarding properties of nicotine [27] . We found no significant difference between genotypes with this schedule of reinforcement for 0.03 mg/kg of nicotine, i.e., on their breaking point measured as the number of reinforcements received during the test ( Figure 2E ). However, a5SNP rats reached a significantly higher breaking point than WT rats for the dose of 0.06 mg/kg ( Figure 2E ). This result suggests that the higher nicotine intake at 0.06 mg/kg by a5SNP rats is most likely due to greater motivation or lesser aversion for this dose of nicotine.
In and Ex Vivo Electrophysiology of VTA DA Neurons in a5SNP, a5KO, and WT Rats Considering the importance of VTA DA neurons in the acquisition of SA of psychostimulants in general and of nicotine in particular [28, 29], we recorded in vivo the electrophysiological properties of these neurons under baseline conditions and their response to intravenous injection of nicotine in a5KO, a5SNP, and WT rats (see STAR Methods). We did not observe any differences between genotypes in the spontaneous activity of these neurons, neither in terms of firing frequency nor in terms of bursting activity ( Figure 3A ). However, whereas DA neurons of WT and a5SNP rats increased their firing frequency in response to 0.03 mg/kg of nicotine, DA neurons of a5KO rats did not respond to this dose and increased their frequency only in response to the highest dose of nicotine (0.09 mg/kg; Figure 3B ; the VTA DA neurons response of WT and a5SNP rats to the 0.09 mg/kg nicotine dose is not available). This is in agreement with VTA DA neurons of a5KO rats exhibiting much weaker responses to saturating concentration of the nicotinic agonist dimethylphenylpiperazinium (DMPP) in brain slices, compared to WT and a5SNP rats ( Figure 3C ). These electrophysiological results highlight the importance of the a5 subunit of nAChRs in the activity of DA neurons of the VTA in response to nicotine and may explain why a5KO rats failed to acquire the nicotine-SA at 0.03 mg/kg. It thus provides a neurobiological correlate of our behavioral results.
Reinstatement of Nicotine Seeking after Extinction in a5SNP and WT Rats
An extinction phase was then conducted by withholding nicotine and its associated visual cue, inducing a progressive and similar decrease of the responding of a5SNP and WT rats on the active lever until stabilization ( Figure 4A ). After stable extinction, rats were tested for reinstatement of nicotine seeking induced by cue, cue + nicotine (0.1 mg/kg, subcutaneous [s.c.]), or nicotine priming alone (0.1 mg/kg, s.c.) in comparison with extinction sessions with saline priming injections (see STAR Methods). WT and a5SNP rats exhibited a similar cue-induced reinstatement of nicotine seeking. In contrast, a5SNP rats had a significantly higher level of reinstatement after exposure to either cue + nicotine or nicotine alone, compared to WT rats ( Figure 4B ), Figure 1 . Creation and Validation of a5KO and a5SNP Rats (A) Creation of a5KO rats. ZFNs containing 5 or 6 fingers were designed to target coding sequences of interest at the beginning of the exon 5 of CHRNA5 gene for site-specific double-strand break (DSB) in the DNA. ZFNs were injected into the pronucleus of rat one-cell embryos (mRNA, 2 ng/mL). This induced a 184-bp deletion in the gene after non-homologous end joining (NHEJ), verified by sequencing and alignment with WT sequence (lower case) and by PCR followed by migration on a 2% agarose gel. (B) Creation of a5SNP rats. ZFNs containing 5 fingers were designed to target coding sequences of interest (gray lines) at the end of the exon 5 of CHRNA5, 50 bp away from the potential site of the a5SNP (codons circled in red) for site-specific DSB in the DNA. ZFNs were injected into the pronucleus of rat one-cell embryos (mRNA, 2 ng/mL) with a plasmid containing the a5SNP in the middle of a 1,600-bp DNA sequence homologous to the WT sequence. This induced the insertion of the a5SNP after homologous recombination (HR), verified by sequencing and alignment with WT sequence (lowercase) and by PCR followed by Taq 1 restriction enzyme digestion and migration on a 2% agarose gel. (C and D) Levels of expression of the a5*nAChR (C) and of total heteromeric nicotinic receptors (D) in homozygous a5KO, a5SNP, and WT rats. Experiments were performed with immunoprecipitation with subunit-specific antibodies (in fmol/mg of tissue) in the interpeduncular nucleus (IPN), medial habenula (mHb), hippocampus (Hpc), striatum (Stri), prefrontal cortex (PFC), brain stem (BStem), thalamus (Thal), ventral tegmental area (VTA), and substantia nigra (SN). The overall number of nAChRs was determined by combined immunoprecipitation with anti-b2 plus anti-b4 antibodies. *p < 0.05; **p < 0.01; ***p < 0.001 versus WT (Dunnett's multiple comparison test for each brain area after one-way ANOVA). a5SNP versus WT: non-significant in every brain area. Mean and SEM are represented. See also Figures S1, S2, S3, and S4 and STAR Methods.
suggesting that the presence of the rs16969968 polymorphism leads to higher level of relapse after re-exposure to nicotine, but not to nicotine-associated cues alone.
To confirm and extend these behavioral data, we performed a second nicotine-SA experiment on new groups of a5SNP and WT rats. The acquisition of SA behavior was carried out as before, and we confirmed (1) that both groups acquired the task equally, (2) the absence of difference between genotypes in the pattern of extinction, and (3) the increased level of relapse of a5SNP versus WT rats induced by cue + nicotine or nicotine alone ( Figure 4C ), with no difference in inactive lever presses ( Figure S5 ). This highlights the robustness, reproducibility, and specificity of the nicotine-induced high-relapsing phenotype observed in a5SNP rats.
Neuronal Activation during Nicotine-Induced Reinstatement of Nicotine Seeking
In order to dissect the effect of the rs16969968 polymorphism on relapse, we investigated the expression of the c-Fos immediate early gene product, considered as a marker of neuronal (B) Number of food pellets earned during the food self-administration training (continuous reinforcement, no associated cues) from self-administration experiment 1 in WT, a5SNP, and a5KO rats. WT (n = 17), a5SNP (n = 16), and a5KO (n = 15) are shown. The two-way ANOVA performed on the number of food pellets self-administered revealed no significant effect of genotype (F 2,45 = 0.35; p = 0.7; NS) but a significant effect of session (F 4,180 = 65.38; p < 0.0001) and no interaction (F 8,180 = 1.13; p = 0.34; NS). Mean and SEM are represented. (C) Amount of nicotine (mg/kg) consumed during nicotine (0.01-0.09 mg/kg/infusion)-SA under FR5 schedule of reinforcement in WT and a5SNP rats (N = 9 per group). The two-way ANOVA indicated a significant effect of nicotine concentration (F 3,48 = 17.16; p < 0.0001), genotype (F 1,16 = 7.62; p = 0.014), and interaction (F 3,48 = 4.08; p = 0.01). Post hoc analysis (Bonferroni's multiple comparison test): WT versus a5SNP: *p < 0.05 for 0.06 mg/kg/infusion; **p < 0.01 for 0.09 mg/kg/infusion. Mean and SEM are represented. (D) Saline substitution. Number of active lever presses in WT (n = 8) and a5SNP rats (n = 9) during four consecutive sessions with saline substituted to nicotine and nicotine-associated cues still present (from the first self-administration experiment) is shown. The two-way ANOVA indicated a significant effect of session (F 3,45 = 31.53; p < 0.0001), but not of genotype (F 1,15 = 0.02; p = 0.89; NS) or interaction (F 3,45 = 0.52; p = 0.65; NS). Mean and SEM are represented. (E) Number of reinforcements and last ratio completed in WT and a5SNP rats under a progressive ratio of reinforcement schedule at the nicotine doses of 0.03 and 0.06 mg/kg/injection. The two-way ANOVA indicated a significant effect of genotype (F 1,18 = 7.47; p = 0.013), a non-significant effect of nicotine concentration (F 1,18 = 0.206; NS), and a significant interaction (F 1,18 = 4.48; p = 0.048). Post hoc analysis (Bonferroni's multiple comparison test): WT versus a5SNP: p = 0.09 (NS) for 0.03 mg/kg/infusion and p = 0.0068 for 0.06 mg/kg/infusion (**). WT rats: n = 9; a5SNP rats: n = 11. Mean and SEM are represented. See also STAR Methods. activation [30], during nicotine-induced reinstatement of nicotine-seeking sessions in multiple brain areas (see STAR Methods). Nicotine-induced reinstatement of nicotine seeking was associated with an increase of c-Fos expression in several brain areas in both WT and a5SNP rats compared to saline condition ( Figure 5A ). Interestingly, a significantly higher expression was observed in the medial part of the lateral habenula (LHbm) and the lateral hypothalamus (LH) of a5SNP rats compared to WT rats ( Figure 5B ), two structures that have been previously associated with relapse to drug seeking [31, 32] . Conversely, a lower c-Fos expression was observed in the IPN of a5SNP compared to WT rats ( Figures 5A and 5B) , and the number of c-Fos-positive cells in the IPN was negatively correlated with the level of reinstatement of nicotine seeking ( Figure 5C ). Considering the high expression of the a5 nAChR subunit in the IPN ( Figure 1C ), these results suggest a major role of this structure in the participation of the rs16969968 polymorphism on nicotine-induced reinstatement of nicotine seeking. In order to investigate whether the lower activation of IPN neurons of a5SNP rats is related to the density of nicotinic currents in this structure, we recorded ex vivo the electrophysiological response to nicotine of IPN neurons of naive WT, a5SNP, and a5KO rats. We observed that nicotine-evoked currents were strongly reduced in both a5SNP and a5KO rats compared to WT rats, without a significant difference between a5SNP and a5KO rats ( Figure 5D ). This result indicates that the deficit in IPN neuron reactivity to nicotine in a5SNP rats is already present before chronic nicotine self-administration and may represent a constitutive predisposition factor for relapse to nicotine seeking.
DISCUSSION
Creation of the a5SNP and a5KO Rats
In humans, the a5SNP (rs16969968), which is frequent in the general population, has been robustly associated with an increased risk for nicotine dependence and lung cancer [6, 8, 9] . However, the type of behavior related to nicotine addiction affected by this polymorphism, such as acquisition, motivation for the drug or Rats, Have Dopamine Neurons that Respond to Low Nicotine (A) Spontaneous VTA DA neuron frequency and bursting activity recorded in vivo in WT, a5SNP, and a5KO rats. Plot of mean firing frequency (Hz) against percentage of spikes within a burst (% SWB) for n = 34 individual cells in WT (blue), n = 19 in a5SNP (black), and n = 18 in a5KO (red) rats is shown; ns (p > 0.05; Wilcoxon test with corrections). Four main functional sub-populations are delineated by gray masks. These sub-populations are indicative of four different relationships between firing rate and %SWB (low firing low burst; low firing high burst; low firing high burst; high firing high burst). (B) VTA DA neurons of WT and a5SNP rats respond to low dose of nicotine, and a5KO rats VTA DA neurons require higher nicotine. Left: typical electrophysiological recording depicting the changes in firing pattern elicited by 0.03 mg/kg intravenous (i.v.) nicotine injection (dashed line) in wild-type (WT), a5KO, and a5SNP rats is shown. Middle: DA cell firing activity at 0.03 mg/kg/injection for n = 34 individual cells in WT (blue), n = 19 in a5SNP (black), and n = 18 in a5KO (red) rats and at 0.09 mg/kg/injection for a5KO rats, compared to baseline is shown. Post hoc Wilcoxon test: *p < 0.05. Right: mean ± SEM of increased response from baseline in firing activity of WT (blue), a5SNP (black), and a5KO (red) rats for indicated nicotine concentrations (time of injection indicated by vertical dashed blue lines) is shown. Mean and SEM are represented. (C) VTA DA neurons of a5KO rats exhibit a lower response to a saturating dose of DMPP (100 mM) than WT and a5SNP rats. The left panel illustrates typical voltage responses of neurons to depolarizing and hyperpolarizing current pulses in acute slices. Middle: histogram of current responses normalized to the response in WT rat is shown. WT (n = 10) versus a5KO (n = 15): z = 141, ***p = 0.00083; a5KO versus a5SNP: z = 90.5, p = 0.00017; WT versus a5SNP (n = 16): z = 24.5, p = 0.59; NS; Mann-Whitney test. Right: local application of DMPP induces an inward current in voltage clamp recording of neurons from WT, a5KO, and a5SNP rats. Mean and SEM are represented. See also STAR Methods. relapse, and the neuronal mechanism involved, are not perfectly understood.
Only transgenic mice have been used so far to study the role of distinct nicotinic receptor subtypes in behavioral and neurophysiological functions over the past decades, mostly because of the lack of tools to efficiently manipulate the rat genome. These studies showed that the lack of a5, constitutively or locally in the mHb, confers an increase of nicotine-SA at high doses [16, 17] and an increase in anxiety [33] . Interestingly, the expression of the a5SNP in the VTA or the hippocampus (Hpc) of a5KO mice did not fully restore the phenotypes, contrary to the re-expression of the WT a5 subunit [17, 33] . This can be explained by the partial loss of function of a5*nAChRs induced by the a5SNP as shown in vitro [6, [13] [14] [15] . Such studies have provided important information, but they did not model the human situation where the presence of the a5SNP is constitutive or investigate the impact of the a5SNP on relapse to nicotine seeking, a hallmark of nicotine addiction. Several technologies have been recently developed for targeted gene disruption in zygotes, including engineered nonspecific nucleases that are fused to sequence-specific DNA binding domains, such as ZFNs and transcription activatorlike effector nucleases (TALENs), and CRISPR-associated Cas9 nucleases [22] .
In the present study, we generated transgenic knockouts for the a5 nicotinic receptor subunit and knockin rats constitutively expressing the a5SNP using ZFN technology. At the optimal concentration and form (2 ng/mL, mRNA), the ZFN pair used for a5KO rats induced genetic modifications (mostly deletions from 10 to 184 bp) in 55% of the cases and the ZFN pair used for a5SNP rats co-administered with a homologous DNA template containing the a5SNP led to the creation of a5SNP rats with a rate of 11.5%. These rates are high and comparable to what has been obtained with the most recent CRISPR/Cas9 technique but without the frequent off-target effect usually associated with this technique [21, 22] .
These results underscore the usefulness of using the genomeediting tools recently developed, and in particular the ZFN technology, to create better animal models of human conditions with good specificity in a short time frame.
These novel rat models allowed us to study the involvement of the a5 nAChR subunit and the rs16969968 polymorphism in (B) Reinstatement of nicotine seeking (active lever presses) after extinction (with saline-priming injections) induced by visual cue, cue + nicotine (0.1 mg/kg), and nicotine alone (0.1 mg/kg) in WT and a5SNP rats from experiment 1. The two-way ANOVA performed on cue-induced reinstatement (n = 9 per group) indicated a significant effect of reinstatement (F 1,16 = 32.9; p < 0.0001), but not of genotype (F 1,16 = 0.001; p = 0.97; NS) nor interaction (F 1,16 = 0.011; p = 0.74). ###p < 0.0001 on extinction versus reinstatement for both genotypes (Bonferroni's multiple comparison test). The two-way ANOVA performed on cue + nicotine-induced reinstatement (WT rats: n = 9; a5SNP rats: n = 8) indicated a significant effect of reinstatement (F 1,15 = 31.63; p < 0.0001), genotype (F 1,15 = 7.9; p = 0.0132), and interaction (F 1,15 = 11.66; p = 0.0038). Post hoc analysis (Bonferroni's multiple comparison test) WT versus a5SNP: p < 0.001 (***) on reinstatement (NS on extinction). ###p < 0.0001 on extinction versus reinstatement for both genotypes. The two-way ANOVA performed on nicotine-induced reinstatement (n = 9 per group) indicated a significant effect of reinstatement (F 1,16 = 27.6; p < 0.0001), genotype (F 1,16 = 8.2; p = 0.011), and interaction (F 1,16 = 11.95; p = 0.0033). Post hoc analysis (Bonferroni's multiple comparison test) WT versus a5SNP: p < 0.001 (***) on reinstatement (NS on extinction). ###p < 0.0001 on extinction versus reinstatement for a5SNP, but not WT rats (NS). Mean and SEM are represented.
(C) Reinstatement of nicotine seeking (active lever presses) after extinction (with saline-priming injections) induced by cue + nicotine (0.1 mg/kg) and nicotine alone (0.1 mg/kg) in WT and a5SNP rats from experiment 2. The twoway ANOVA performed on cue + nicotine-induced reinstatement (WT rats: n = 9; a5SNP rats: n = 10) indicated a significant effect of reinstatement (F 1,17 = 68.03; p < 0.0001), genotype (F 1,17 = 9.92; p = 0.0058), and interaction (F 1,17 = 11; p = 0.0041). Post hoc analysis (Bonferroni's multiple comparison test) WT versus a5SNP: p < 0.001 (***) on reinstatement (NS on extinction). ###p < 0.0001 on extinction versus reinstatement for both genotypes. The two-way ANOVA performed on nicotine-induced reinstatement (WT rats: n = 9; a5SNP rats: n = 10) indicated a significant effect of reinstatement (F 1,17 = 13.46; p = 0.0019), genotype (F 1,17 = 13.9; p = 0.0017), and interaction (F 1,17 = 21.42; p = 0.0002). Post hoc analysis (Bonferroni's multiple comparison test) WT versus a5SNP: p < 0.001 (***) on reinstatement (NS on extinction). ###p < 0.0001 on extinction versus reinstatement for a5SNP, but not WT rats (NS). Mean and SEM are represented. See also Figure S5 and STAR Methods.
behaviors more difficult to attain in mice models, such as longterm self-administration and reinstatement of nicotine seeking.
Phenotypes of a5SNP and a5KO Rats in Nicotine Self-Administration and Relapse
We showed that a5*nAChRs are necessary for the establishment of nicotine-SA and nicotine-induced activity of DA neurons in the VTA at 0.03 mg/kg. This is consistent with a previous report showing that a5KO mice are self-administering nicotine only at high doses and not when the dose is around 0.03 mg/kg/injection [17] , but not with another study indicating that these mice acquire nicotine (0.03 mg/kg/injection) SA as well as WT mice [16] , although it is difficult to extrapolate the efficiency of specific nicotine doses between mice and rats due to differences in nicotine metabolism [34] . Yet this observation supports the idea that a5*nAChRs strongly contribute to the sensitivity to nicotine as previously shown for several functions in mice [17, 33, 35] .
In addition, a5SNP rats were able to acquire the nicotine-SA at 0.03 mg/kg as well as WT rats but self-administered significantly more nicotine at high doses in fixed and progressive ratio procedures. This result is in line with a previous study from our lab showing that the expression of the a5SNP in VTA's dopaminergic neurons of a5KO mice induced nicotine-SA at higher doses than with the re-expression of the WT subunit [17] . 46 ; p = 0.0002), anterior cingulate cortex (AC) (F 1,23 = 27.19; p < 0.0001), orbitofrontal cortex (OF) (F 1,23 = 13.54; p = 0.0012), shell and core of the nucleus accumbens (shell, F 1,23 = 16.19; p = 0.0005 and core, F 1,23 = 18.82; p = 0.0002), basolateral and central amygdala (BLA, F 1,14 = 9.85; p = 0.0073 and CeA F 1,14 = 6.76; p = 0.021), septum (Sept) (F 1,23 = 13.23; p = 0.014), medial part of the lateral habenula (LHbm) (F 1,22 = 14.6; p = 0.0009), lateral hypothalamus (LH) (F 1,24 = 28.09; p < 0.0001), posterior ventral tegmental area (pVTA) (F 1,22 = 6.7; p = 0.017), and interpeduncular nucleus (IPN) (F 1,24 = 23.2; p < 0.0001). The genotype and interaction (genotype X treatment) effects were only significant in the IPN (F 1,24 = 5.69, p = 0.025 and F 1,24 = 5.636, p = 0.026, respectively), the LHbm (F 1,22 = 9.181, p = 0.0061 and F 1,22 = 57.45, p = 0.0122, respectively), and the LH (F 1,24 = 6.41, p = 0.0183 and F 1,24 = 5.152, p = 0.0325, respectively). Post hoc analysis (Bonferroni's multiple comparison test) WT versus a5SNP: **p < 0.01 on reinstatement (NS on extinction with saline condition). Saline versus nicotine: ###p < 0.0001; ##p < 0.01; #p < 0.05. Mean and SEM are represented. (B) Representative c-Fos immunofluorescence in the IPN (red) performed on brain slices of WT and a5SNP rats after nicotine-induced reinstatement of nicotine seeking test. The horizontal white bar represents 50 mm. This c-Fos expression has been observed in two independent experiments. (C) Correlation between the number of c-Fos-positive cells in the IPN and the level of reinstatement during the nicotine-induced reinstatement of nicotine seeking test. WT rats (blue, n = 10) and a5SNP rats (black, n = 11) are shown. Two-tailed Spearman R = À0.69; p = 0.0005. (D) Ex vivo nicotine-evoked current in IPN neurons of WT, a5SNP, and a5KO rats. Current amplitudes following a puff application of nicotine (30 mM, 200 ms) on IPN neurons were larger in WT rats (n = 19) than a5SNP (Holm-Bonferroni corrected U-test; n = 20; *p = 0.0486) and a5KO rats (n = 15; **p = 0.0092). The Kruskal-Wallis testing (one-way ANOVA; H-test) for the 3 group comparison shows a robust genotypic effect (p = 0.00387; chi-square = 11.1088 and df = 2). See also STAR Methods.
Thus, the increase in nicotine-SA at high doses might be due to the presence of the a5SNP in dopaminergic neurons of the VTA, but we cannot dismiss a potential role of the mHb in this effect, because it has been described as a key structure in the control of nicotine intake and aversion in mice [16, 36] .
We also discovered that, although the a5SNP does not contribute to extinction behavior after chronic nicotine-SA or to cue-induced reinstatement of nicotine seeking, it reproducibly increases nicotine-induced reinstatement of nicotine seeking. This constitutes an important finding, considering the high frequency of relapse in nicotine addiction.
Taken together, our data demonstrate that the rs16969968 polymorphism is a major factor for nicotine intake at high doses and for relapse to nicotine seeking in rats, a dual effect that may explain the increased risk for nicotine dependence and delayed smoking cessation observed in humans [6, 8, 9] .
Neuronal Activation during Nicotine-Induced Relapse: Implication of the IPN Finally, we found that the a5SNP increased the neuronal activity in the LH and the medial division of the LHb during nicotineinduced reinstatement of nicotine seeking but decreased the neuronal activity in the IPN. The neuronal activity in the IPN was negatively correlated to the level of nicotine-induced reinstatement of nicotine seeking, suggesting an important role of this structure in the increase in relapse induced by nicotine in a5SNP rats. We also showed on brain slices that the rs16969968 polymorphism confers a profound deficit in the reactivity of IPN neurons to nicotine, comparable to the absence of the a5 subunit. This is in line with the decrease in the function of nAChRs in response to nicotine induced by the polymorphism, as previously reported in a study showing that the lack of a5 prevents nicotine-evoked elevations of intracellular-free calcium concentration and large-amplitude currents, a deficit that is not restored by the expression of the a5SNP [14] . In addition, an in vitro study found the a5SNP induces a reduced response to nicotinic agonists when extracellular calcium is high [37] . It also suggests that the deficit in reactivity to nicotine of IPN neurons represents a constitutive predisposition factor to relapse to nicotine seeking.
The IPN has been previously involved in avoidance of aversive stimuli [38, 39] , locomotor activity [40] , nicotine withdrawal [41] and sensitization [42] , and morphine-, methamphetamine-, and nicotine-SA [43] [44] [45] . The IPN is a primarily GABAergic (>95%) [12] brain nucleus that contains the majority of the a5 nAChR subunit in the rat brain ( Figure 1C ) and projects, among others, to the LH [46] . Glutamatergic axons from the LH target glutamatergic neurons in the medial division of the LHb [47] . Interestingly, both LH and LHb have been involved in relapse to cocaine [32, [48] [49] [50] , heroin [31], and alcohol [51] [52] [53] seeking. In addition, a recent study showed that the specific LH to LHb projection is necessary for regulating voluntary ethanol consumption [54] . Along this line, modulating the activity of IPN neurons may represent a novel research area to impact relapse to drugs of abuse.
In our study, activation of a5-containing GABAergic projection neurons in the IPN may inhibit the activity of the LH-LHbm circuit. This suggests that, in WT rats, activation by nicotine of a5-containing GABAergic projection neurons from this structure acts as a ''brake'' to limit relapse to nicotine seeking and that this brake is being lifted by the presence of the rs16969968 polymorphism.
Considering that the majority of nAChR a5 subunits are present in the IPN of the rat's brain, the development of a class of therapeutic compounds designed to specifically enhance the activity of a5*nAChRs, such as positive allosteric modulators, may represent a novel personalized strategy with high specificity to prevent relapse to tobacco smoking in populations carrying the rs16969968 polymorphism.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Rats
Long-Evans (WT) male (7 weeks) and females (4 weeks) rats and were purchased from Janvier Lab. Pseudopregnant Dark Agouti females were purchased from Janvier Lab. a5KO and a5SNP rats were generated, bred and housed at Institut Pasteur, Paris, France. Male, Long Evans WT, a5KO and a5SNP rats experimentally naive at the start of the study and initially weighing 250 to 275 g were used for all behavioral experiments. All rats were individually housed in a temperature-controlled environment on a 12-h reverse light/dark cycle (lights off from 08:00 hours to 20:00 hours) at the start of the behavioral experiments. All the experimental procedures described in this report were approved by the institutional Animal Care Committee (agreement no. 0355.02). All efforts were made to minimize animal suffering, and to reduce the number of animals required. Use of a repeated-measures design contributed to the latter.
METHOD DETAILS
Creation of the a5KO and A5SNP rats ZFN constructs specific for the rat nAChR a5 subunit gene were designed, assembled, and validated by Sigma-Aldrich, St. Louis, MO, USA. They target the beginning of exon 5 (Zinc Finger Nuclease Binding/cutting site CCCTACATCACGTACTCCtttgtGAT TAAGCGGCTGCC) for the creation of a5KO rats and the end of the exon 5, 50bp away from rs16969968 polymorphism location (Zinc Finger Nuclease Binding/cutting site CTCGATTGCATTCGCtacatCACGAGGCACGTCGTG) for the creation of the a5SNP rats. mRNA or plasmid encoding the nAChR a5 subunit ZFNs were injected into 1-cell Long-Evans rat embryos (pronuclear injection, continuous flow), with a template of DNA with 1603bp homology and containing the a5SNP at its center for the creation of the a5SNP rats. Viable embryos were transferred into pseudopregnant Dark Agouti females (Janvier LABS). For the a5KO line, the heterozygote founder rat no. 18 was chosen for the subsequent experiments because of a large deletion of 184 bp in the coding sequence associated with the introduction of a stop codon. For the a5SNP line, the heterozygote founder rat no. 20 was chosen for the subsequent experiments because of the presence of the a5SNP without other modifications. The founder rats was crossed with a WT Long-Evans rat (Janvier LABS) and the transmission of the deleted allele was confirmed by genotyping. The heterozygous F1 rats were crossed together to obtain the homozygous a5KO and a5SNP lines and the corresponding WT lines. a5KO mRNA or plasmid encoding the nAChR a5 subunit ZFNs were diluted in microinjection buffer (10 mM Tris, 0.1 mM EDTA, pH 7.4) at a concentration of 2 ng/mL or 6 ng/mL and injected into 1-cell Long-Evans rat embryos (pronuclear injection, continuous flow). 483 embryos were injected with the a5KO ZFNs mRNA while 286 embryos were injected with the a5KO ZFN plasmid. After microinjection, 254 and 130 viable embryos, respectively, were transferred into pseudopregnant Dark Agouti females (Janvier LABS). 29 pups were born from the embryos injected with the mRNA form (20 from the injection at 2 ng/mL and 9 from the injection at 6 ng/mL) and 11 pups were born from the embryos injected with the plasmid form (7 from the injection at 2 ng/mL and 4 from the injection at 6 ng/mL). At 3 weeks of age, a small piece of tail was cut, and DNA was extracted with phenol/chloroform/Isoamyl Alcohol and screened for ZFN-induced mutations. Briefly, DNA extracted from tail tissue was amplified using primers flanking the above target sequence Software and Algorithms a5KO-F (5 0 AATTCGGCTCGTGGACATAC3 0 ) and a5KO-R (5 0 CCAAGTACTCCCCAATCAGG 3 0 ). PCR products (393 bp) were heat denatured, reannealed (95 C, 2 min; 95 to 85 C, À2 C/s; 85 to 25 C, À0.1 C/s; 4 C indefinitely), and subjected to cleavage by the Surveyor Nuclease (Cel-I; Transgenomic) at 42 C for 20 min according to the manufacturer's instructions. Ten microliters of each reaction were loaded on a 10% Tris/Borate/EDTA (TBE) polyacrylamide gel (Thermofisher Scientific) and poststained with a solution of TBE with Ethidium bromide. Among the 11 pups born (embryos injected with the a5KO ZFNs plasmid), 0 positive animal was identified; while among the 29 pups born (embryos injected with the a5KO ZFNs mRNA), 12 positive rats were identified (11 from the 2 ng/mL dose and 1 from the 6 ng/mL dose). The PCR products of 11 founders obtained with the 2 ng/mL dose were integrated into a PGEMT-easy plasmid (Promega) according to the manufacturer's instructions and at least 8 clones per founder was sequenced using T7 and SP6 universal primers by Cogenics. We observed mostly deletions, from 10 to 184 base pairs (bp), and in most cases a stop codon was introduced. The results are summarized in Figure S1 . a5SNP A template of DNA with 1603bp homology and containing the a5SNP at its center was created by amplifying 1603 bp of genomic DNA from a WT Long-Evans rat with the following primers:
The DNA fragment was then inserted into a pGEMT-easy plasmid and the a5SNP was inserted by targeted mutagenesis by using the following primers: Forward: 5 0 GGAAGCCGCACTCAATTGCATTCGCTACATC3 0 Reverse: 5 0 GATGTAGCGAATGCAATTGAGTGCGGCTTCC3 0 mRNA encoding the nAChR a5 subunit ZFNs and the plasmid containing the 1603bp template of DNA with the a5SNP were both diluted in microinjection buffer (10 mM Tris, 0.1 mM EDTA, pH 7.4) at a concentration of 2 ng/mL and injected into 1-cell Long-Evans rat embryos (pronuclear injection, continuous flow). 332 embryos were injected and 174 viable embryos were transferred into pseudopregnant Dark Agouti females (Janvier LABS). 26 pups were born. At 3 weeks of age, a small piece of tail was cut, and DNA was extracted and screened for the presence of the a5SNP. Briefly, DNA extracted from tail tissue was amplified using primers flanking the above target sequence a5SNP-F (5 0 CTCCACACACAACGCTATGG 3 0 ) and a5SNP-R (5 0 CTTCAGGATCATTCAAGGCG 3 0 ). PCR products (308 bp) were digested at 65 C with the restriction enzyme Taq1 (Thermofisher Scientific), because the presence of the a5SNP removes the restriction site for this enzyme. Twenty microliters of each reaction were loaded on a 2% agarose gel with Ethidium bromide. Among the 26 pups born, 4 potential positive rats were identified and 1603bp of their genomic DNA covering the a5SNP have been sequenced as above. The presence of the a5SNP without other modifications has been detected in 3 rats (no. 3, 20 and 24); no. 16 rat presented a deletion of 32 bp covering the a5SNP. The heterozygote founder rat no. 20 was chosen for the subsequent experiments.
Off-target site prediction
To identify putative off-target sequences based on similarities with the recognition sequences of the ZFNs, the most current assembly of the rat genome (RGSCv3.4) were scanned (up to 8 mismatches for ZFN heterodimers for the a5KO rats and up to 7 mismatches for ZFN heterodimers for the a5SNP rats). 3 potential off-target sites were identified for the a5KO rats and 11 for the a5SNP rats. PCR primers were designed to amplify these regions. The PCR products were then submitted to the Surveyor nuclease assay as described above for detection of mismatches. No off-target activity was detected in both founders (see Figures S3 and S4) .
Immunoprecipitation
Brain dissection
Brains of wild-type and transgenic male Long-Evans rats were extracted, flash-frozen and dissected into the different brain regions: interpeduncular nucleus (IPN), habenula, hippocampus, striatum, prefrontal cortex, brain stem, thalamus, vental tegmental area (VTA) and substantia nigra. Those areas are well identified by their anatomical landmarks and are known to be rich in a5-containing nAChRs. Samples were collected in Ca 2+ -free Tyrode's solution: 150 mM NaCl, 4 mM KCl, 2.0 mM MgCl 2 , 10 mM glucose, and 10 mM HEPES, pH 7.4. After removal of the Tyrode's solution, tissue was flash-frozen with liquid nitrogen and stored at À80 C for later use. Subunit-specific antibodies All antibodies used in this study were raised against the cytoplasmic loop domain of the respective nAChR subunit (a5, b2, and b4). The antibodies were first described by our group in [55] . The immunoprecipitation experiments have been conducted as previously described [56, 57] .
Immunoprecipitation (IP) of [3H]-epibatidine-labeled receptors
To obtain enough protein for one assay, 3-4 rats were required per brain region. For immunoprecipitation, tissue samples were solubilized in 2% Triton X-100 lysis buffer (50 mM Tris-HCl pH = 7.5, 150 mM NaCl, 2% Triton X-100, supplemented with one complete mini protease inhibitor cocktail tablet (Roche Molecular Biochemicals, Indianapolis, IN, USA) per 10 mL buffer). Subsequently, samples were sonicated on ice for 5 s and incubated at 4 C for 2 hr. They were then centrifuged at 16,000 g for 15 min at 4 C. The supernatant (containing the solubilized proteins) was collected and the pellet was discarded. An aliquot of 50 mL was collected and stored at À20 C for protein quantification. 130 mL lysate was incubated with 20 mL 10 nM [3H]-epibatidine and 5 mg antibody in 30 mL phosphate-buffered saline (pH = 7.4) on a shaker overnight at 4 C. Non-specific binding was defined by the addition of an excessive amount of nicotine (300 mM) before the addition of radioactive epibatidine to half of the samples.
Heat-killed, formalin-fixed Staphylococcus aureus cells (Standardized Pansorbin-cells; Calbiochem; San Diego, CA, USA) were centrifuged at 2300 g for 5 min at 4 C. Resulting Pansorbin-pellets were washed twice with IP-High (50 mM Tris-HCl, 600 mM NaCl, 1 mM EDTA, 0.5% Triton X-100; pH 8.3) and once with IP-Low (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.2% Triton X-100; pH 8.0), and then re-suspended with IP-Low. A volume of 20 mL of the washed Pansorbin was added to the samples which were subsequently incubated on a shaker for 2 hr at 4 C. After the incubation with Pansorbin, the samples were centrifuged at 2300 g for 5 min at 4 C. The supernatant was then discarded, and the pellet which contained the complex Pansorbin-nAChR-[3H] Epibatidine was washed twice with IP-High and once with IP-Low with the samples being centrifuged once more at 2300 g for 1 min at 4 C after each wash. To re-suspend the pellets, 200 mL 1 M NaOH was added and the suspensions were then transferred into 6 mL Mini Vial Sarstedt tubes. A volume of 2 mL scintillation cocktail (Rotszint Eco Plus, Carl Roth, Karlsruhe, Germany) was added per tube and liquid scintillation counting was then performed. Bicinchoninic acid assays were performed to determine the total protein concentration according to the manufacturer's instructions using the BCA Protein Assay Reagent Kit (Pierce, Rockford, IL, USA).
In vivo electrophysiological recordings
Adult male Long-Evens rats (6-12 weeks) were anesthetized with chloral hydrate (8%), 400 mg/kg i.p. supplemented as required to maintain optimal anesthesia throughout the experiment, and positioned in a stereotaxic frame. A hole was drilled in the skull above midbrain DA nuclei (coordinates: 5 ± 1.5 mm posterior to bregma, 1 ± 1 mm [VTA] lateral to the midline). Recording electrodes were pulled from borosilicate glass capillaries (with outer and inner diameters of 1.50 and 1.17 mm, respectively) with a Narishige electrode puller. The tips were broken under microscope control and filled with 0.5% sodium acetate. Electrodes had tip diameters of 1-2 mm and impedances of 20-50 MU. A reference electrode was placed in the subcutaneous tissue. The recording electrodes were lowered vertically through the hole with a micro drive. Electrical signals were amplified by a high-impedance amplifier and monitored with an oscilloscope and an audio monitor. The unit activity was digitized at 25 kHz and stored in Spike2 program. Its margins ranged from À4.9 to À5.9 mm posterior to bregma (AP), 0.5 to 1 mm mediolateral (ML) and 7 to 8.5 mm ventral (DV). Sampling was initiated on the right side and then on the left side.
The electrophysiological characteristics of DA neurons were analyzed in the active cells encountered when systematically passing the microelectrode in a stereotaxically defined block of brain tissue including the VTA. Extracellular identification of DA neurons was based on their location as well as on the set of unique electrophysiological properties that distinguish DA from non-DA neurons in vivo (2): (i) a typical triphasic action potential with a marked negative deflection; (ii) a long duration (> 2.0 ms); (iii) an action potential width from start to negative trough > 1.1 ms; (iv) a slow firing rate (< 10 Hz and > 1 Hz).
Catheters are placed into saphenous veins for saline or nicotine i.v. administration. After 10 min of baseline recording, a first saline solution (NaCl 0.9%) was injected as control for nicotine injection. Nicotine (0.03 mg/kg) was injected 10 min after the saline solution. n = 34 individual cells in WT, n = 19 in a5SNP and n = 18 in a5KO rats have been recorded.
Ex vivo whole-cell patch clamp recordings Slice preparation 6-8 week old male Long Evans rats were deeply anesthetized with an i.p. injection of a mix of ketamine (75 mg/kg, intraperitoneal (IP)) and xylazine (10 mg/kg, IP). Coronal midbrain sections (250 mm) were sliced using either a Compresstome (VF-200; Precisionary Instruments, Greenville, NC) or a vibratome (VT1000S; Leica) after intracardial perfusion of cold (4 C) sucrose-based artificial cerebrospinal fluid (SB-aCSF). Slices were then transferred to a recording chamber continuously perfused at 2 mL/min with oxygenated aCSF. Patch pipettes (4-8 MU) were filled with a KGlu based intra-pipette solution. 100 mM) was applied through a local perfusion system in the presence of a cocktail of antagonists: 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX, 1uM), 2-amino-5-phosphonovalerate (APV, 50mM), Gabazine (GBZ, 1mM), haloperidol (2uM), atropine (8mM) and CGP55845 (4mM). DMPP, CNQX, APV, Gabazine, haloperidol and atropine were purchased from Sigma (Saint Louis, MO, USA) and CGP55845 from Tocris (Bristol, GB) and all of them were dissolved in water. Number of neurons recorded (n): WT (n = 10), a5KO (n = 15) and a5SNP (n = 16).
Nicotine self-administration
Male, Long Evans rats experimentally naive at the start of the study and initially weighing 250 to 275 g were used for all behavioral experiments. All rats were individually housed in a temperature-controlled environment on a 12-h reverse light/dark cycle (lights off from 08:00 hours to 20:00 hours). All efforts were made to minimize animal suffering, and to reduce the number of animals required. Use of a repeated-measures design contributed to the latter. SA sessions were carried out in experimental chambers equipped with two levers (Med Associates, St. Albans, Vt., USA), as previously described [58] [59] [60] . (-)Nicotine hydrogen tartrate (Sigma-Aldrich, St Louis, Mo., USA) was dissolved in saline and administered intravenously (IV) in a volume of 100 ml/kg/injection or subcutaneously (SC) in a volume of 1 mL/kg.
Self-administration procedures
Rats were trained to press a lever on a schedule in which each press resulted in the delivery of a 45 mg food pellet (continuous reinforcement, CRF, no associated cues). Once trained, each animal was surgically prepared with a chronic intravenous catheter implanted in the jugular vein; the catheters exited between the scapulae. Surgery was performed under anesthesia induced by xylazine (10 mg/kg, intraperitoneal (IP)) and ketamine hydrochloride (75 mg/kg, IP). Incision sites were infiltrated with the local anesthetic bupivacaine (0.125%). Buprenorphine was given for post-operative analgesia (0.01 mg/kg, subcutaneous (SC)), and a single dose of penicillin (30,000 units, SC) was administered before surgical procedures. Rats were allowed to recover for a 1-week period before drug SA sessions were begun.
First self-administration experiment Acquisition
In the first experiment, a5SNP (n = 15), a5KO (n = 15) and WT (n = 14) rats acquired nicotine SA under a FR schedule of reinforcement and the unit dose was 0.03 mg/kg per infusion of nicotine base. During the first week of acquisition, each lever press during the time-in period resulted in the delivery of an infusion (FR-1). The next 2 weeks, response requirements were increased to the final value of FR-5 (i.e., rats were required to make five lever presses for each drug infusion). Rats were considered to have acquired stable nicotine SA when they pressed the active lever more than twice the number of times they pressed the inactive lever, and received a minimum of 5 infusions per 1-h session with less than 20% variation in the number of infusions earned per session during 2 consecutive sessions.
Dose-response curve
The rats that had successfully acquired the behavior (all of the WT and a5SNP rats, none of the a5KO rats) were then submitted to SA of different doses of nicotine (0.01; 0.03; 0.06 and 0.09 mg/kg/infusion) according to a latin-square design; with at least 3 sessions for each dose and a stable responding required, with intermediate sessions at the 0.03 mg/kg/infusion training dose between each testing with another dose. Only rats that had completed the testing for all nicotine doses were included for analysis (n = 9 for WT and n = 9 for a5SNP rats). After this testing, the WT and a5SNP rats were submitted to 4 consecutive sessions with saline substituted to nicotine and the nicotine-associated cues still present (n = 8 for WT and n = 9 for a5SNP rats. One WT rat was not submitted to the saline substitution sessions due to momentary sickness). Nicotine SA at the training dose was then re-established before the extinction phase. Extinction The extinction phase was conducted by withholding nicotine and its associated cues. Responses on the active or inactive lever were recorded, but had no consequences (n = 9 for WT and n = 9 for a5SNP rats). The criterion for extinction was less than 20 active lever presses per 1 hr session with less than 20% variation over 2 consecutive days. Reinstatement of nicotine seeking After significant and stable extinction, cue-induced reinstatement test was conducted under conditions identical to that of SA, except that 1) a single presentation of the visual cue (light above the active lever for 10 s) was delivered response-independently immediately at the start of the session and 2) responses on the active lever resulted in contingent presentation of the cues (light above the active lever on and house-light off for 20 s) without nicotine availability (no infusions). The testing sessions lasted 1 hr (n = 9 per group).
After the testing for cue-induced reinstatement and subsequent extinction, rats were tested for cue+nicotine-induced reinstatement of nicotine seeking. Nicotine priming consisted of a SC injection of nicotine at 0.1 mg/kg, 10 min before the test-session. The conditions for cues presentation were the same as for the cue-induced reinstatement of nicotine seeking (WT rats: n = 9; a5SNP rats: n = 8. One a5SNP rat was not submitted to cue+nicotine-induced reinstatement of nicotine seeking session due to momentary sickness).
After the testing for cue+nicotine-induced reinstatement and subsequent extinction, rats were tested for nicotine-induced reinstatement of nicotine seeking. Nicotine priming consisted of a SC injection of nicotine at 0.1 mg/kg, 10 min before the test-session (n = 9 per group). No cues were presented.
The extinction sessions performed before the reinstatement sessions induced by Cue+nicotine or nicotine alone were done with saline priming injection, 10 min before the extinction session.
In vivo Electrophysiological data
Statistics and electrophysiological recordings of DA cell activity were analyzed using R (http://www.r-project.org), a language and environment for statistical computing. DA cell firing was analyzed with respect to the average firing rate and the percentage of spikes within a burst (%SWB, number of spikes within a burst divided by the total number of spikes). Bursts were identified as discrete events consisting of a sequence of spikes which onset is defined by two consecutive spikes within an interval < 80 ms, and that terminate with an interval >160 ms23, 24, 46. Firing rate x and %SWB were evaluated on successive windows of 60 s, with a 45 s overlapping period. To quantify nicotine effects, each cell's activity was rescaled by its averaged baseline value x0 (for the firing frequency) and %SWB0 (for the bursting), estimated over a 3min period before nicotine injection. For the firing frequency x, the rescaling X, expressed as % of the baseline, is defined by X = x*100/x0. For the busting parameter, we used the difference from the value during baseline Y = %SWB-%SWB0. For each neuron, we determined Xbef, the maximum of fluctuation before substance injection (during 3min used as baseline), and Xaft the maximum of fluctuation after injection (during 3min after injection). Because of non-normal distributions of data (Shapiro test), effects of nicotine were analyzed using a paired non-parametric Wilcoxon test to compare Xbef (Ybef) with Xaft (Yaft) for firing frequency and %SWB, respectively. Differences were considered significant if p < 0.05. Data are expressed as mean ± standard deviation of the mean (SEM). For each nicotine injection using the Wilcoxon paired test, the null hypothesis is that the location parameters of the distribution are the same before and after nicotine injection. Differences were considered significant if p < 0.05. To study differences between WT, a5SNP and a5KO rat dose-response curves, we used the Kruskall Wallis nonparametric test, and statistical significance was set at p < 0.05.
Ex vivo whole-cell patch clamp recordings of IPN neurons
For each distribution, normality was tested using a Shapiro-Wilk test. To test for a genotypic effect we ran a Kruskal-Wallis test (nonparametric one-way analysis of variance, H-Test) for the three groups. Comparisons between groups (WT versus a5KO, WT versus a5SNP and a5KO versus a5SNP) were tested using a non-parametric Mann-Whitney-Wilcoxon rank-sum test (U-Test) when parameters followed a non-normal distribution (Shapiro test, p < 0.05). We applied a Holm-Bonferroni correction for multiple-comparison to adjust p values. p > 0.05 was considered to be not statistically significant. All statistics were calculated using R.
Nicotine self-administration
Nicotine self-administration data were subjected to repeated-measures ANOVAs, followed when appropriate by post hoc Bonferroni for multiple comparisons. Changes were considered significant when p < 0.05.
For the data on nicotine SA under the PR schedule, the statistical analysis has been made on the total number of injections received during the session before 30 min without any active lever press (BP).
c-Fos counting
The number of c-Fos positive nuclei was automatically counted with the spot detector module of ICY software (Institut Pasteur, Paris, France). This program makes possible to select and count cells automatically without experimenter bias (counts were conducted without knowledge of the group assignments). In each coronal section, we sampled both ipsi-and contralateral regions separately and then averaged the density of the spots for each structure per animal. The results were expressed as number of c-Fos positive cell per square millimeter of cerebral tissue.
Statistics were analyzed using Prism software. Data from each brain area were subjected to two-way ANOVAs followed when appropriate by post hoc Bonferroni for multiple comparisons. Changes were considered significant when p < 0.05.
